RPL17 and melanoma: Recent studies have shown that anti-PD-1 mAb treatment in cutaneous carcinoma and melanoma patients resulted in the emergence of new TCR clonotypes in the TME, suggesting de novo priming of tumor-reactive T cells in the periphery (Liu et al., 2022; Nagasaki et al., 2022; Wu et al., 2020; Yost et al., 2019).